The increased <i>in vitro</i> phagocytic activity of resKCs and recMφs against FITC-<i>E</i>. <i>coli</i> and the decreased TNF-α production by LPS-stimulated liver MNCs following... by Takuya Ishikiriyama (6735674)

Fig 5 - by Amanda C. Hahn (17241106)

Three-, bi- and mono-functional Vγ9Vδ2 T-cell subsets decrease in HIV+ patients. by Rita Casetti (608635)

Land use at 6kya (6,250–5,750 years ago). by J. Bates (17507061)

Prenatal alcohol exposure (PAE) decreases brain and body weights at E14 and P0. by Danielle Sambo (6077924)

Evolution of the adjusted geometric mean plasma values of homocysteine from baseline through the 4.7 years of follow-up (with adjustment for sex, baseline plasma creatinine, type o... by Leopold K. Fezeu (5309333)

Subcellular location and expression of Halo-zDHHC20 and Halo-zDHHC5 in Flp-In 293 T-REx cells. by Mingjie Bai (10028513)

Subjects:

<i>l</i>-THP decreased level of NO, ONOO⁻ and iNOS, regulated expression of p85, eNOS and Akt. by Yi Han (194901)

“…Serine⁴⁷³ phosphorylation of Akt was significantly increased in <i>l</i>-THP (M)-treated group, but total Akt expression was not increased, ^#P<0.05 vs. sham group, *P<0.05 vs. vehicle group, n = 5. (<b>f</b>) Cardiac ONOO⁻ generation, as measured by luminol-enhanced chemiluminescence, in each of the five groups, ^#P<0.05 vs. sham group, *P<0.05, **P<0.01 vs. vehicle group, n = 6. …”

V2 vasopressin receptor abundance. by Sophie Constantin Lütken (689916)

Subjects:

Intrathecal injection of mycolactone triggers a decrease of pro-inflammatory cytokines in spinal cord of Sham rats. by Caroline Isaac (4600654)

(A-C) Force versus drill depth and torque versus drill depth. by Marsel Ganeyev (21453399)

Cell death and reactive gliosis induced by severe IVH showed a decrease after dexamethasone treatment. by Jang Hoon Lee (5897096)

Increase of proliferating progenitor cells and decrease of terminally differentiated granule neurons in the immature dentate gyrus of <i>PC3/Tis21</i>-null mice at P14. by Stefano Farioli-Vecchioli (256006)

“…<p>(<b>A</b>) The whole population of progenitor cells entering in S-phase, labeled by a short pulse of BrdU (1hour) and by the progenitor cell marker Sox2 (BrdU/Sox2-positive), increased significantly in <i>PC3/Tis21</i>-null mice (1.6-fold). …”

Fig 6 - by Maria Alice Miranda Bezerra Medeiros (11752002)

Transforming growth factor (TGF)-β1 induced a robust decrease in S-phase in non-cancer cell strains by Kimberly A Brown (26546)

“…Representative histograms are presented illustrating cells that had a robust decrease in S-phase (NMuMG), modest decrease in S-phase (EpH4), and no decrease in S-phase (MDA-MB-436) as a result of TGF-βtreatment. …”

Mean value of ENSS and subscales. by Phu Dinh Vu (19429477)

Subjects:

<i>Mdk</i>-deficient mice aged 9 months displayed increased trabecular number and decreased cortical thickness in the femur. by Melanie Haffner-Luntzer (504724)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”